COMPLETED

Continuous Glucose Monitoring in the Intensive Care Unit

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of the proposed clinical trial is to study the use of the Dexcom G7 continuous glucose monitor (CGM) within the intensive care unit (ICU) environment. The overall goal is to validate the accuracy and practicality of the Dexcom G7 when used to assess glycemia in critically ill patients.

Official Title

Continuous Glucose Monitoring in the Intensive Care Unit: Validation and Implementation

Quick Facts

Study Start:2024-02-20
Study Completion:2025-07-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06190808

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Persons with either type 1 or type 2 diabetes.
  2. * Persons of either sex.
  3. * Persons of any age over 18.
  4. * Persons able to give informed consent or cognitively impaired adults whose legally authorized representative (LAR) can give informed consent.
  5. * English or Spanish speaking adults.
  1. * Persons unable to provide informed consent.
  2. * Cognitively impaired persons whose LAR declines to provide informed consent.
  3. * Patients receiving hydroxyurea, which interferes with sensor function.
  4. * Patients receiving high dose acetaminophen (\> 4 gm/day), which interferes with sensor function.
  5. * Anasarca affecting preferred areas for device placement (arm, upper buttocks, or thigh), which may interfere with sensor accuracy.
  6. * Severe cachexia with absence of subcutaneous fat at preferred sensor placement sites, which might interfere with sensor accuracy.
  7. * Persons who are pregnant.
  8. * Prisoners.

Contacts and Locations

Principal Investigator

John P Mordes, MD
PRINCIPAL_INVESTIGATOR
UMass Chan Medical School

Study Locations (Sites)

UMass Memorial Medical Center
Worcester, Massachusetts, 01605
United States

Collaborators and Investigators

Sponsor: University of Massachusetts, Worcester

  • John P Mordes, MD, PRINCIPAL_INVESTIGATOR, UMass Chan Medical School

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-20
Study Completion Date2025-07-25

Study Record Updates

Study Start Date2024-02-20
Study Completion Date2025-07-25

Terms related to this study

Keywords Provided by Researchers

  • ICU
  • CGM
  • Accuracy
  • Diabetes
  • Hypoglycemia
  • Diabetes mellitus
  • Continuous glucose monitor
  • Intensive care

Additional Relevant MeSH Terms

  • Diabetes Mellitus